Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality.

Autor: Elmowafy AY; Urology and Nephrology Center, Mansoura University, Mansoura, Egypt., El Maghrabi HM; Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.; Nephrology Department, Port-Said University, Port Fuad, Egypt., Eldahshan KF; Urology and Nephrology Center, Mansoura University, Mansoura, Egypt., Refaie AF; Urology and Nephrology Center, Mansoura University, Mansoura, Egypt., Elbasiony MA; Egyptian Liver Research Institute and Hospital, Mansoura, Egypt.; Internal Medicine Department, Mansoura University, Mansoura, Egypt., Matter YE; Urology and Nephrology Center, Mansoura University, Mansoura, Egypt., Saleh HH; Urology and Nephrology Center, Mansoura University, Mansoura, Egypt., Shiha GE; Internal Medicine Department, Mansoura University, Mansoura, Egypt., Rostaing L; Service de Néphrologie, Dialyse, Aphérèses et Transplantation Rénale, CHU Grenoble Alpes, CS 10217, 38043, Grenoble Cedex 09, France. LRostaing@chu-grenoble.fr., Bakr MA; Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Jazyk: angličtina
Zdroj: International urology and nephrology [Int Urol Nephrol] 2019 Sep; Vol. 51 (9), pp. 1639-1647. Date of Electronic Publication: 2019 Jul 30.
DOI: 10.1007/s11255-019-02246-7
Abstrakt: Background and Aims: New direct-acting antiviral drugs have become the corner-stone treatment for HCV infection: they show promising results with accepted side-effects and low dropout rates. One of the available regimens is paritaprevir/ombitasvir/ritonavir (PTV/OMV/RTV). Our aim was to study the efficacy and safety of this drug regimen among HCV-positive hemodialysis patients.
Methods: This prospective single-center study was performed in the Urology and Nephrology Center, Mansoura University, Egypt. Ninety-six maintenance hemodialysis patients were screened for HCV antibodies. Positive results were found in 46 patients (47.9%). HCV PCR was assessed in all HCV-antibody-positive patients; positive results were found positive for 38 (82%); all patients were HCV genotype 4. Four patients were excluded due to advanced liver cirrhosis, liver malignancy, or metastatic breast cancer. Thirty-four patients were prescribed PTV/OMV/RTV for 3 months to treat HCV.
Results: Mean age was 43.2 ± 11.9 years. Most patients were male (67.6%). There was a rapid response to treatment: HCV PCR became negative by 4 weeks after starting treatment. By 12 and 24 weeks post-DAA therapy, there was a sustained viral response (SVR 12, SVR 24) in 100% of patients with improved liver-enzyme levels.
Conclusion: The PTV/OMV/RTV regimen was safe and effectively treated Egyptian HCV-positive genotype-4 hemodialysis patients.
Databáze: MEDLINE
Externí odkaz: